Risk of Neurological Adverse Events Between PD-L1 and PD-1 Inhibitors in South Korean Patients with Lung Cancer: A Target Trial Emulation Framework

Sang Hee Kim, Seung Hyeun Lee, Sukhyang Lee, Sun-Young Chang, Ha-Lim Jeon, Hankil Lee · 2026

Read Risk of Neurological Adverse Events Between PD-L1 and PD-1 Inhibitors in South Korean Patients with Lung Cancer: A Target Trial Emulation Framework by Sang Hee Kim, Seung Hyeun Lee, Sukhyang Lee, Sun-Young Chang, Ha-Lim Jeon, Hankil Lee (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13612710.txt.

Description

Sang Hee Kim and colleagues present a 2026 South Korean study comparing nerve-related side effects of two groups of cancer immunotherapy drugs in people with lung cancer. One group blocks a protein called PD-1, and the other blocks its partner, PD-L1. Such side effects are uncommon, yet they can be serious, so knowing whether one drug group carries more risk helps doctors choose and monitor treatment.

Using nationwide health data and a design that mimics a clinical trial, the team matched 931 patients in each group. Nerve problems in the limbs were more common with PD-L1 drugs overall, at 19.2 percent against 14.1 percent. Timing differed too: early problems within 30 days were more common with PD-1 drugs, while the pattern shifted after three months.

Catalog record

CREATORSang Hee Kim, Seung Hyeun Lee, Sukhyang Lee, Sun-Young Chang, Ha-Lim Jeon, Hankil Lee
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE46 KB
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13612710

Browse the full library · About the Tower of Babel